WO2006090273A3 - [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia - Google Patents

[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia Download PDF

Info

Publication number
WO2006090273A3
WO2006090273A3 PCT/IB2006/000477 IB2006000477W WO2006090273A3 WO 2006090273 A3 WO2006090273 A3 WO 2006090273A3 IB 2006000477 W IB2006000477 W IB 2006000477W WO 2006090273 A3 WO2006090273 A3 WO 2006090273A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
naphthyridin
schizophrenia
keto
ones
Prior art date
Application number
PCT/IB2006/000477
Other languages
French (fr)
Other versions
WO2006090273A2 (en
Inventor
Douglas Scott Johnson
Jamie Marie Singer
Andrew David White
Original Assignee
Warner Lambert Co
Douglas Scott Johnson
Jamie Marie Singer
Andrew David White
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Douglas Scott Johnson, Jamie Marie Singer, Andrew David White filed Critical Warner Lambert Co
Publication of WO2006090273A2 publication Critical patent/WO2006090273A2/en
Publication of WO2006090273A3 publication Critical patent/WO2006090273A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) are disclosed. A of formula 1 is -(CH2)mCO- or -(CH2)mCOH-, wherein m is an integer from 2 to 5 and wherein one or two of the carbon atoms can be substituted as described in the specification. G, D, Z, Q, X, Y, R1, and R4 through R7 of formula 1 are defined in the specification. Also provided are descriptions of processes for preparing compounds of formula 1, intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.
PCT/IB2006/000477 2005-02-22 2006-02-14 [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia WO2006090273A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65511805P 2005-02-22 2005-02-22
US60/655,118 2005-02-22

Publications (2)

Publication Number Publication Date
WO2006090273A2 WO2006090273A2 (en) 2006-08-31
WO2006090273A3 true WO2006090273A3 (en) 2006-10-05

Family

ID=36717070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000477 WO2006090273A2 (en) 2005-02-22 2006-02-14 [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia

Country Status (1)

Country Link
WO (1) WO2006090273A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015675A (en) 2005-07-04 2008-02-20 Novo Nordisk As Hists1mine h3 receptor antagonists.
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2010151711A1 (en) * 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
PL2445502T5 (en) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8536328B2 (en) 2010-05-04 2013-09-17 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
ES2691671T3 (en) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN104230903A (en) * 2013-06-15 2014-12-24 广东东阳光药业有限公司 Method for preparing antidepressant drug vilazodone
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106608875A (en) * 2015-10-26 2017-05-03 江苏恩华药业股份有限公司 Synthesis and application of fused heterocycle derivative
JP7384812B2 (en) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド Aripiprazole dosing strategy
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO2002060423A2 (en) * 2001-01-29 2002-08-08 Otsuka Pharmaceutical Co., Ltd. Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2004026864A1 (en) * 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029048A1 (en) * 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2005019215A1 (en) * 2003-08-22 2005-03-03 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO2002060423A2 (en) * 2001-01-29 2002-08-08 Otsuka Pharmaceutical Co., Ltd. Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2004026864A1 (en) * 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029048A1 (en) * 2002-09-26 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2005019215A1 (en) * 2003-08-22 2005-03-03 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARY MCCORT ET AL..: "Synthesis and SAR of 3- and 4- substituted Quinolin-2-ones: Discovery of mixed 5-HT1b/5-HT2a Receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 9, no. 8, August 2001 (2001-08-01), GBELSEVIER SCIENCE LTD., pages 2129 - 2137, XP002391169 *

Also Published As

Publication number Publication date
WO2006090273A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006090273A3 (en) [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP2266622A3 (en) Prodrugs containing novel bio-cleavable linkers
EP2269657A3 (en) Prodrugs containing novel bio-cleavable linkers
NZ595571A (en) Pyrazole compounds and uses thereof
EP1725536B8 (en) Imidazoline derivatives having cb1-antagonistic activity
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
TW200628154A (en) Organic compounds
MX2007013021A (en) Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists.
MX2007004637A (en) Asymmetric synthesis of dihydrobenzofuran derivatives.
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
WO2009025839A3 (en) Phosphodiesterase 10 inhibitors
MY142474A (en) 1h-quinazoline-2,4-diones
TW200716547A (en) Piperidin-4-yl-amide derivatives
TN2009000483A1 (en) 7-ALKYNYL-1-8-NAPHTHYRIDONES DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
TW200714282A (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
WO2008057575A3 (en) Novel arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
WO2006112742A3 (en) PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES
HK1090354A1 (en) Novel dibenzo [b,f]oxepine-10-carboxamides and pharmaceutical uses thereof
WO2008052088A8 (en) Chromane derivatives, synthesis thereof, and intermediates thereto
WO2008059513A3 (en) Compounds suitable as modulators of hdl
WO2006061372A3 (en) Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06710500

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6710500

Country of ref document: EP